Search clinical trials for: olaparib durvalumab

Total 1083 results

Brown University
Lifespan

Active, not recruiting

Durvalumab and Consolidation SBRT Following Chemoradiation for Locally Advanced Stage III Non-Small Cell Lung (358)

Stage III Non-small-cell Lung Cancer

United States
Case Comprehensive Cancer Center

Terminated

Proton Based Cardiac Sparing Accelerated Fractionated RadioTherapy in Unresectable NSCLC

Non-Small Cell Lung Cancer

United States
Memorial Sloan Kettering Cancer Center
Novartis Pharmaceuticals

Active, not recruiting

A Study of Canakinumab With Chemotherapy, Radiation Therapy, and Durvalumab in People With Lung Cancer (CHORUS)

Non-small Cell Lung Cancer

United States
Ludwig Institute for Cancer Research
Cancer Research Institute, New York City; MedImmune LLC

Completed

A Phase 1 Study to Evaluate MEDI4736 in Combination With Tremelimumab

Renal Cell Carcinoma | Cervical Cancer | Breast Cancer | Colorectal Cancer | Ovarian Cancer

United States
University of Colorado, Denver
AstraZeneca

Withdrawn

A Study of Durvalumab in Patients With BR PDA Following Neoadjuvant Therapy and Successful Surgical Resection

Pancreatic Cancer

United States
University of Maryland, Baltimore

Withdrawn

Durvalumab Plus "Booster" RT for Metastatic Adenocarcinoma Pancreas Cancer Post Chemotherapy (GCC 1598) (Panc-Durval+RT)

Metastatic Pancreas Cancer
The University of Hong Kong

Recruiting

Effects of PARP Inhibitor on Tumor Microenvironment in High-risk Endometrial Cancer Patients

Endometrial Cancer

Hong Kong
Institute of Cancer Research, United Kingdom
AstraZeneca; Cancer Research UK

Recruiting

ATr Inhibitor in Combination With Olaparib in Gynaecological Cancers With ARId1A Loss or no Loss (ATARI)

Gynaecological Cancers

United Kingdom
Matthew Galsky
Icahn School of Medicine at Mount Sinai; AstraZeneca

Completed

Trial of Olaparib in Patients With Metastatic Urothelial Cancer Harboring DNA Damage Response Gene Alterations

Metastatic Urothelial Cancer

United States
AstraZeneca

Completed

To Assess the Efficacy and Safety of Olaparib Maintenance Monotherapy in the Treatment of Ovarian Cancer (ORZORA)

BRCA or HRR+ Mutated Ovarian Cancer Patients

Italy, Spain, Canada, Czechia, Poland, United Kingdom, Hungary, Bulgaria
Gustave Roussy, Cancer Campus, Grand Paris

Unknown

Trial Evaluating Maintenance Olaparib in Patients With Platinum-sensitive Advanced Non-small Cell Lung Cancer (PIPSeN)

Non Small Cell Lung Cancer

France
Dana-Farber Cancer Institute

Withdrawn

Olaparib for Patients With Recurrent BRCA Deficient Ovarian Cancer

Ovarian Cancer | Fallopian Tube Cancer | Peritoneal Cancer

United States
Institut für Klinische Krebsforschung IKF GmbH...
Hannover Medical School; AstraZeneca

Recruiting

Durvalumab and Tremelimumab in Combination With Either Y-90 SIRT or DEB-TACE for Intermediate Stage HCC

HCC | Hepatocellular Carcinoma Non-resectable

Germany
Azienda Ospedaliero-Universitaria Careggi

Not yet recruiting

Durvalumab, Cetuximab and Radiotherapy in Head Neck Cancer (DUCRO-HN)

Head and Neck Neoplasms
BeiGene

Terminated

A Study to Compare Ociperlimab Plus Tislelizumab Versus Durvalumab Following Concurrent Chemoradiotherapy (cCRT) in Patients With Stage III Unresectable Non-Small Cell Lung Cancer

Non Small Cell Lung Cancer

China, Taiwan, Australia, United States
H. Lee Moffitt Cancer Center and Research Institute
AstraZeneca; Brooklyn ImmunoTherapeutics, LLC

Active, not recruiting

IRX-2 Regimen and Durvalumab, for Incurable H&N Squamous Cell Carcinoma

Squamous Cell Carcinoma of the Head and Neck | Oropharynx Squamous Cell Carcinoma | Squamous Cell Carcinoma | Oral Cavity Squamous Cell Carcinoma | Metastatic Squamous Cell Carcinoma | Hypopharynx Squamous Cell Carcinoma | Paranasal Sinus Squamous Cell Carcinoma | Larynx Squamous Cell Carcinoma

United States
MedImmune LLC

Completed

Neoadjuvant Durvalumab Alone or in Combination With Novel Agents in Resectable Non-Small Cell Lung Cancer

NSCLC | Resectable | Early-stage

United States, Canada, Switzerland, Italy, France, Portugal, Spain
OHSU Knight Cancer Institute
Oregon Health and Science University; Prospect Creek Foundation

Completed

Olaparib and Durvalumab in Treating Participants With Metastatic Triple Negative Breast Cancer

Anatomic Stage IV Breast Cancer AJCC v8 | Prognostic Stage IV Breast Cancer AJCC v8 | Estrogen Receptor Negative | HER2/Neu Negative | Progesterone Receptor Negative | Triple-Negative Breast Carcinoma

United States
M.D. Anderson Cancer Center
Merck Sharp & Dohme LLC; AstraZeneca

Active, not recruiting

Study of Olaparib Maintenance Following Cabazitaxel-Carbo in Men With AVPC

Prostate Carcinoma | Prostate Cancer Aggressiveness

United States
National Cancer Institute (NCI)

Recruiting

Testing the Safety of the Anti-Cancer Drugs Durvalumab and Olaparib During Radiation Therapy for Locally Advanced Unresectable Pancreatic Cancer

Stage II Pancreatic Cancer AJCC v8 | Stage III Pancreatic Cancer AJCC v8 | Unresectable Pancreatic Carcinoma | Locally Advanced Pancreatic Carcinoma

United States, Canada
University Health Network, Toronto
Centre for Addiction and Mental Health

Recruiting

Psilocybin-Assisted Psychotherapy for Treatment-Resistant Depression: Comparing One Versus Two Doses of Psilocybin (PSI-1V2)

Depression | Mood Disorders | Major Depressive Disorder | Treatment-Resistant Depression

Canada
National Taiwan University Hospital
AstraZeneca

Recruiting

Olaparib Maintenance Therapy in Metastatic Breast Cancer

Metastatic Breast Cancer

Taiwan
Peter MacCallum Cancer Centre, Australia

Recruiting

177Lu-PSMA-617 Therapy and Olaparib in Patients With Metastatic Castration Resistant Prostate Cancer (LuPARP)

Metastatic Castration Resistant Prostate Cancer (mCRPC)

Australia
Tango Therapeutics, Inc.

Terminated

Study to Evaluate TNG348 Alone and With a PARP Inhibitor in Patients With BRCA 1/2 Mutant or HRD+ Solid Tumors

Breast Cancer | Ovarian Cancer | Prostate Cancer | Pancreas Cancer | BRCA1 Mutation | BRCA-Mutated Ovarian Carcinoma | BRCA-Associated Breast Carcinoma | HRD Positive Advanced Ovarian Cancer

United States
Institut Bergonié
National Cancer Institute, France

Completed

A Study of Olaparib With Concomitant Radiotherapy in Locally Advanced/Unresectable Soft-tissue Sarcoma (RADIOSARP)

Soft-tissue Sarcoma

France
Seoul National University Hospital

Active, not recruiting

Phase II Study of Durvalumab ,Doxorubicin, and Ifosfamide in Pulmonary Sarcomatoid Carcinoma

Carcinoma, Non-Small-Cell Lung

Korea, Republic of
The University of Hong Kong
Queen Mary Hospital, Hong Kong

Recruiting

Immunotherapy and Radioembolisation for Metastatic Hepatocellular Carcinoma

Hepatocellular Carcinoma

Hong Kong
Ottawa Hospital Research Institute
AstraZeneca; Hamilton Health Sciences Corporation; London Health Sciences Centre and other collaborators

Recruiting

Radiation and Durvalumab Immunotherapy As Neoadjuvant Treatment for MIBC (RADIANT)

Bladder Cancer

Canada
SOLTI Breast Cancer Research Group

Recruiting

Predicting Olaparib Sensitivity in Patients With Unresectable Locally Advanced/Metastatic HER2-negative Breast Cancer. (RADIOLA)

Metastatic Breast Cancer | Triple Negative Breast Cancer | HER2-negative Breast Cancer

Spain
Laval University
Canadian Institutes of Health Research (CIHR); AstraZeneca

Recruiting

Olaparib for PAH: a Multicenter Clinical Trial (OPTION)

Pulmonary Arterial Hypertension

Canada
Dana-Farber Cancer Institute
AstraZeneca

Withdrawn

Olaparib in Unresectable/Metastatic Melanoma With BRCA1/2

Uveal Melanoma | Cutaneous Melanoma | Mucosal Melanoma | Recurrent Metastatic Melanoma

United States
AstraZeneca

Active, not recruiting

Olaparib Real-world Utilization and Clinical Outcomes in France, Italy, and the UK (OVAL-1)

Ovary Cancer

France, United Kingdom
University of Texas Southwestern Medical Center

Completed

PARP Inhibition During Pre-surgical Window in Breast/Ovary Cancer

Breast Cancer | Ovarian Cancer

United States
Mirati Therapeutics Inc.

Terminated

Phase 1/2 Study of Mocetinostat and Durvalumab in Patients With Advanced Solid Tumors and NSCLC

Advanced Cancer

United States
Rachel Sanborn
AstraZeneca; Providence Cancer Center, Earle A. Chiles Research Institute

Active, not recruiting

Durvalumab Followed by Chemoradiation and Consolidation Durvalumab for Stage III Non-small Cell Lung Cancer

Lung Cancer | Non-small Cell Carcinoma

United States
AstraZeneca

Completed

A Global Study to Assess the Effects of MEDI4736 (Durvalumab), Given as Monotherapy or in Combination With Tremelimumab Determined by PD-L1 Expression Versus Standard of Care in Patients With Locally Advanced or Metastatic Non Small Cell Lung Cancer (ARCTIC)

Non - Small Cell Lung Cancer NSCLC

United States, France, Germany, Italy, United Kingdom, Belgium, Poland, Romania, Taiwan, Thailand, Canada, Korea, Republic of, Czechia, Hungary, Japan, Russian Federation, Hong Kong, Spain, Netherlands, Greece, Australia, Serbia, Bu... and more
AstraZeneca
Merck Sharp & Dohme LLC; NRG Oncology; Breast International Group; Myriad Genetic... and other collaborators

Active, not recruiting

Olaparib as Adjuvant Treatment in Patients With Germline BRCA Mutated High Risk HER2 Negative Primary Breast Cancer (OlympiA)

Breast Cancer

United States, Austria, Italy, Spain, Sweden, United Kingdom, Belgium, Poland, France, Switzerland, Canada, Germany, Korea, Republic of, Netherlands, Japan, China, Taiwan, Australia, Argentina, Israel, Hungary, Portugal, Iceland, Puerto...
University College, London
AstraZeneca; Cancer Research UK

Active, not recruiting

Phase I Study of Olaparib Combined With Cisplatin-based Chemoradiotherapy to Treat Locally Advanced Head and Neck Cancer (ORCA-2)

Head and Neck Cancer

United Kingdom
AstraZeneca
Parexel; Covance; Iqvia Pty Ltd; Theradex; Myriad Genetics, Inc.

Completed

Multicentre Study of Olaparib Maintenance Monotherapy in Platinum Sensitive Relapsed Non gBRCAm Ovarian Cancer Patients (OPINION)

Non-Germline BRCA Mutated Ovarian Cancer

Italy, Spain, Sweden, Canada, Czechia, Poland, United Kingdom, Israel, Austria, Belgium, Switzerland, Netherlands, Bulgaria, Finland, Norway, Denmark, Slovenia, Portugal
AstraZeneca

Completed

AZD5153 in Patients With Relapsed or Refractory Solid Tumors, Including Lymphomas

Lymphoma | Breast Cancer | Pancreatic Cancer | Ovarian Cancer | Prostate Cancer | Malignant Solid Tumors

United States, Canada
Istituto Scientifico Romagnolo per lo Studio e...

Unknown

Olaparib as Salvage Treatment for Cisplatin-resistant Germ Cell Tumor

Neoplasms, Germ Cell and Embryonal

Italy
AstraZeneca

Active, not recruiting

Study of Durvalumab + Tremelimumab, Durvalumab, and Placebo in Limited Stage Small-Cell Lung Cancer in Patients Who Have Not Progressed Following Concurrent Chemoradiation Therapy (ADRIATIC)

Small Cell Lung Cancer

United States, Canada, Germany, Italy, Netherlands, Spain, Belgium, Poland, Taiwan, Vietnam, Korea, Republic of, Czechia, India, Japan, Russian Federation, Turkey, China, United Kingdom, Argentina
Austin Health
AstraZeneca; Olivia Newton-John Cancer Research Institute

Completed

A Trial of Radiotherapy and Durvalumab in DLBCL and FL (RaDD)

Follicular Lymphoma | Diffuse Large B Cell Lymphoma

Australia
Pharmacyclics LLC.

Completed

A Multi-Center Study of Ibrutinib in Combination With MEDI4736 in Subjects With Relapsed or Refractory Solid Tumors

Breast Cancer | Pancreatic Cancer | Non-Small Cell Lung Cancer

United States
Terence Friedlander, MD
MedImmune LLC

Withdrawn

Radiation Therapy and Durvalumab, With or Without Tremelimumab, in Patients With Bladder Cancer

Bladder Cancer

United States
National Taiwan University Hospital
AstraZeneca; Ministry of Science and Technology, Taiwan, ROC

Recruiting

Durvalumab for Advanced Hepatocellular Carcinoma in Patients With Active Chronic Hepatitis B Virus Infection

Advanced Hepatocellular Carcinoma

Taiwan
Canadian Cancer Trials Group
AstraZeneca

Completed

Durvalumab and Tremelimumab and Best Supportive Care vs Best Supportive Care in Patients With Advanced Colorectal Cancer

Colorectal Cancer

Canada
Catherine Shu

Withdrawn

Study of Durvalumab + Tremelimumab in NSCLC Patients After Adjuvant Treatment

Nonsmall Cell Lung Cancer

United States
Eli Lilly and Company
AstraZeneca

Completed

A Study of Ramucirumab (LY3009806) Plus MEDI4736 in Participants With Advanced Gastrointestinal or Thoracic Malignancies

Hepatocellular Carcinoma | Gastric Cancer | Non-Small Cell Lung Cancer | Gastroesophageal Junction Adenocarcinoma

United States, Spain, Korea, Republic of, Taiwan, Germany, Italy, France, Israel
University Health Network, Toronto
AstraZeneca

Withdrawn

A Phase 2 Study of Durvalumab (MEDI4736) and Oleclumab (MEDI9447) in Multi-Cancer Populations With Correlation to Clinical, Molecular and Immunologic Parameters With DNA MethylaTION (DOMINATION)

Renal Cell Carcinoma | Non Small Cell Lung Cancer

Canada

Search clinical trials for: olaparib durvalumab

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Denmark

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations